Nuvo Research® to Receive US$2.0 Million

Milestone Payment Related to Pliaglis Brazil Approval and Launch 
MISSISSAUGA, ON, Oct. 10, 2013 /CNW/ - Nuvo Research Inc. (TSX:NRI), a 
specialty pharmaceutical company dedicated to building a portfolio of products 
for the topical treatment of pain and the development of its immune modulating 
drug candidate WF10 today announced that the Company has been advised by its 
worldwide Pliaglis licensing partner, Galderma S.A. (Galderma), that Pliaglis 
has been approved for sale and marketing in Brazil and that it expects to 
launch Pliaglis in Brazil in early 2014. This entitles Nuvo to a US$2.0 
million milestone payment that it expects to receive from Galderma in early 
"We are pleased that Pliaglis has been approved for sale and marketing in 
Brazil which is one of the largest potential markets for Pliaglis," said Dr. 
Bradley Galer, President of Nuvo's Pain Group. "Pliaglis is now approved for 
sale and marketing in 16 European countries, the United States, Argentina and 
Brazil with additional approvals expected over the next two years." 
Important Safety Information 
Indication: PLIAGLIS® (lidocaine and tetracaine) Cream 7% / 7% is indicated 
in adults to produce local dermal anaesthesia on intact skin prior to 
dermatological procedures. Contraindications: PLIAGLIS® Cream is 
contraindicated in patients with a known history of sensitivity to lidocaine 
or tetracaine, or local anesthetics of the amide or ester type and is also 
contraindicated in patients with sensitivity to para-aminobenzoic (PABA) or 
any components of the product. Pliaglis should not be used on mucous membranes 
or on broken or irritated skin. Adverse Events: In clinical studies, the 
most common local reactions were erythema (47%), skin discoloration (16%), and 
edema (14%). The most common systemic adverse events were headache, 
vomiting, dizziness, and fever, all of which occurred with a frequency of 
<1%. Warnings/Precautions: Methemoglobinemia has been associated with use of 
local anesthetics such as tetracaine. PLIAGLIS® Cream should be used with 
caution in patients with severe hepatic disease. When using PLIAGLIS® Cream 
in conjunction with other local anesthetic agents, the total dose of 
anesthetic should be considered due to the potential for additive systemic 
toxic effects. Contact with the eyes should be avoided. The treated area 
should not be occluded before removing Pliaglis from the skin. 
You are encouraged to report negative side effects of prescription drugs to 
the FDA. Visit or call 1-800-FDA-1088. 
About Nuvo Research Inc. 
Nuvo (TSX:NRI) is a specialty pharmaceutical company focused on improving 
patient's lives by developing and commercializing innovative products that 
address unmet medical needs. The Company has a diverse portfolio of products 
in the areas of topical pain and immunology. 
Nuvo's marketed products include Pennsaid(®) (a topical treatment for the 
signs and symptoms of osteoarthritis of the knee), Pliaglis (a topical local 
anesthetic) and the heated lidocaine/tetracaine patch (HLT Patch). For 
additional Company information visit 
About Galderma 
Galderma is a global company founded in 1981 committed to delivering 
innovative medical solutions to meet the dermatological needs of people 
throughout their lifetime while serving healthcare professionals around the 
world. The company has 33 wholly-owned affiliates with a worldwide network of 
distributors and more than 4,500 employees. Galderma's extensive product 
portfolio is available in 80 countries and treats a range of dermatological 
conditions including: acne, rosacea, onychomycosis, psoriasis & 
steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical 
solutions for skin senescence. 
With approximately 19% of revenues invested each year to discover and develop 
new products and access innovative technologies, the company is one of the 
world's leading investors in dermatology R&D. Five state-of-the-art R&D 
centers and four manufacturing sites are dedicated to providing a wide range 
of innovative medical solutions which meet the highest standards of safety and 
Strategic brands includeEpiduo(®), Oracea(®), Clobex(®), Differin(®), 
Rozex(®)/MetroGel(®), Silkis(®)/Vectical(®), Tri-Luma(®), Loceryl(®), 
Cetaphil(®), Metvix(®), Azzalure(®), Restylane(®)and Emervel(®). 
Forward-Looking Statements 
Certain statements in this news release constitute forward-looking statements 
within the meaning of applicable securities laws. Forward-looking statements 
include, but are not limited to, statements concerning the Company's future 
objectives, strategies to achieve those objectives, as well as statements with 
respect to management's beliefs, plans, estimates, and intentions, and similar 
statements concerning anticipated future events, results, circumstances, 
performance or expectations that are not historical facts. Forward-looking 
statements generally can be identified by the use of forward-looking 
terminology such as "outlook", "objective", "may", "will", "expect", "intend", 
"estimate", "anticipate", "believe", "should", "plans" or "continue", or 
similar expressions suggesting future outcomes or events. Such 
forward-looking statements reflect management's current beliefs and are based 
on information currently available to management. Forward-looking statements 
involve risks and uncertainties that could cause actual results to differ 
materially from those contemplated by such statements. Factors that could 
cause such differences include the need for additional financing, the current 
economic environment, dependence on sales and marketing partnerships, 
competitive developments, as well as other risk factors included in the 
Company's annual information form dated March 27, 2013 under the heading 
"Risks Factors" and as described from time to time in the reports and 
disclosure documents filed by the Company with Canadian securities regulatory 
agencies and commissions. This list is not exhaustive of the factors that 
may impact the Company's forward-looking statements. These and other factors 
should be considered carefully and readers should not place undue reliance on 
the Company's forward-looking statements. As a result of the foregoing and 
other factors, no assurance can be given as to any such future results, levels 
of activity or achievements and neither the Company nor any other person 
assumes responsibility for the accuracy and completeness of these 
forward-looking statements. The factors underlying current expectations are 
dynamic and subject to change. Although the forward-looking information 
contained in this news release is based upon what management believes are 
reasonable assumptions, there can be no assurance that actual results will be 
consistent with these forward-looking statements. Certain statements 
included in this news release may be considered "financial outlook" for 
purposes of applicable securities laws, and such financial outlook may not be 
appropriate for purposes other than this news release. All forward-looking 
statements in this news release are qualified by these cautionary 
statements. The forward-looking statements contained herein are made as of 
the date of this news release and except as required by applicable law, the 
Company undertakes no obligation to publicly update or revise any 
forward-looking statement, whether as a result of new information, future 
events or otherwise.

SOURCE  Nuvo Research Inc. 
Galderma Karin Falck Public and Media Relations Officer +41 (0) 797226075 
Nuvo Research Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Nuvo Research Inc.
ST: Ontario
-0- Oct/10/2013 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.